RecruitingNot Applicable

Effects of Rigid Taping in Acromioclavicular Joint Degeneration

Turkey (Türkiye)28 participantsStarted 2026-01-01

Plain-language summary

This study will examine whether rigid taping applied to the acromioclavicular (AC) joint can reduce shoulder pain and improve shoulder function in people with AC joint degeneration. Participants with shoulder pain and a confirmed diagnosis of AC joint degeneration will be randomly assigned to one of two groups: (1) rigid taping plus a standardized exercise program or (2) the same exercise program without taping. The program will last 4 weeks, with weekly supervised visits. Pain, shoulder motion, and shoulder function will be assessed at baseline, after the first session (acute effect), at the end of treatment (Week 4), and at a 3-month follow-up.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A clinical diagnosis of acromioclavicular (AC) joint degeneration confirmed by clinical examination and imaging (X-ray, ultrasound, or MRI). * Shoulder pain duration of at least 4 weeks. * Age between 18 and 65 years * Willingness to refrain from any additional treatments outside the study protocol during the study period (e.g., medication changes, injections, or physiotherapy elsewhere) and to provide written informed consent Exclusion Criteria: * Current or previous diagnosis/history of acromioclavicular (AC) joint separation. * Diagnosis of frozen shoulder (adhesive capsulitis). * History of acute trauma or fracture involving the shoulder girdle (e.g., clavicle fracture, shoulder dislocation). * History of shoulder surgery. * Systemic inflammatory joint disease (e.g., rheumatoid arthritis) or other systemic arthropathies. * Skin conditions preventing taping (e.g., rash, open wound, or known tape allergy). * Neuromuscular disease or neurological disorders affecting shoulder function

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Pain Intensity

Timeframe: Baseline (Week 0), immediately after the first session (acute effect), Week 4 (end of intervention), and Month 3 follow-up

Shoulder Range of Motion

Timeframe: Baseline (Week 0), immediately after the first session (acute effect), Week 2, Week 4 (end of intervention), and Month 3 follow-up

Trial details

NCT IDNCT07333417

SponsorHacettepe University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-25

Contact for this trial

Irem Duzgun, PhD, Prof

+90 (312) 305 15 74 iremduzgun@hacettepe.edu.tr

View on ClinicalTrials.gov More Shoulder Pain trials